重启后首家获受理！高瓴入股

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has submitted its IPO application to the Shanghai Stock Exchange, marking the first company accepted under the newly restarted fifth set of listing standards on the Sci-Tech Innovation Board [1][4]. Group 1: Company Overview - Tainuo Maibo was established in 2015 and is an innovative biopharmaceutical company focused on the development of monoclonal antibody drugs [3]. - The company's core product, Staidotamab Injection (Xintimato®), is the world's first recombinant anti-tetanus toxin monoclonal antibody drug, approved for market in February 2025 [3]. - Tainuo Maibo has faced continuous net losses since its establishment, with cumulative unabsorbed losses reaching 1.024 billion yuan by the end of March 2025 [3]. Group 2: Investment and Institutional Involvement - Tainuo Maibo is the first company to apply the qualified institutional investor system, with Hillhouse Capital's subsidiary holding 3.94% of the company's shares prior to the IPO application [3][4]. - The introduction of the qualified institutional investor system aims to leverage the expertise of top venture capital and industry funds to enhance the review process for companies on the Sci-Tech Innovation Board [5][6]. Group 3: Regulatory Context - The acceptance of Tainuo Maibo's IPO application is a practical implementation of the "1+6" new policy aimed at promoting a dual circulation of technology and capital [4]. - The qualified institutional investor system is a pilot program specifically for companies applying under the fifth set of standards, serving as a reference for review rather than a new listing requirement [6].